FDA OKs BridgeBio unit's cholangiocarcinoma therapy

 Pivotal study demonstrated a clinically meaningful rate of tumor shrinkage (overall response rate) and duration of response in patients with previously-treated advanced cholangiocarcinoma (CCA) harboring an FGFR2 fusion or rearrangement

BridgeBio, through its affiliate QED (“BridgeBio”), and Helsinn will co-commercialize TRUSELTIQ in the U.S.

TRUSELTIQ is BridgeBio’s first FDA approved therapeutic in oncology and second approved therapeutic this year

https://finance.yahoo.com/news/bridgebio-pharma-affiliate-qed-therapeutics-183000192.html